37
Participants
Start Date
August 10, 2020
Primary Completion Date
February 17, 2024
Study Completion Date
December 11, 2024
TAEK-VAC-HerBy
TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose defined in stage 1. During stage 2, it may also be administered concurrently with a HER2 antibody(ies) (trastuzumab, pertuzumab).
Georgia Cancer Center Augusta University, Augusta
Mayo Clinic - Jacksonville, Jacksonville
H. Lee Moffitt Cancer Center, Tampa
Mayo Clinic - Rochester, Rochester
Mayo Clinic - Phoenix, Scottsdale
Providence Saint John's Health Center, Santa Monica
Providence Cancer Institute, Portland
University of Washington, Seattle
Massachusetts General Hospital, Boston
Lead Sponsor
Bavarian Nordic
INDUSTRY